Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. AAPL
3. TTAN
4. CHYM
5. USO
6. COO
7. QCOM
8. IRT
9. AEO
10. LEU

Go back to Pre-Open Stock Movers 10/04: (XENE) (ADVM) (OSUR) Higher; (MRNA) (NEO) (IIVI) Lower (more...)

Xenon Pharmaceuticals (XENE) Prices 8.47M Share Offering at $29.50/sh

October 6, 2021 5:44 AM EDT

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $29.50 per common share and the pre-funded warrants are being offered at a price of $29.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering... More

Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement

October 4, 2021 4:05 PM EDT

Xenon Pharmaceuticals (NASDAQ: XENE) files mixed shelf registration statement of:

Common Shares
Preferred Shares
Warrants
Units

... More

Xenon Pharmaceuticals (XENE) PT Raised to $50 at Jefferies

October 4, 2021 11:23 AM EDT

Jefferies analyst Andrew Tsai raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $50.00 (from $28.00) while maintaining a Buy rating.

... More

Xenon Pharmaceuticals (XENE) PT Raised to $44 at Stifel

October 4, 2021 10:39 AM EDT

Stifel analyst Paul Matteis raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $44.00 (from $31.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy Rating and updating our price target to $44 to reflect the better-than-expected efficacy... More